Gemini Therapeutics, Inc. /DE·4

Apr 7, 4:03 PM ET

Meyenburg Jason Patrick 4

4 · Gemini Therapeutics, Inc. /DE · Filed Apr 7, 2021

Insider Transaction Report

Form 4
Period: 2021-02-05
Meyenburg Jason Patrick
DirectorPresident & CEO
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-02-05+1,124,8321,124,832 total
    Exercise: $12.66Exp: 2031-02-04Common Stock (1,124,832 underlying)
Footnotes (1)
  • [F1]This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

Documents

1 file
  • 4
    ownership.xmlPrimary